HLS Operating Income from 2010 to 2026

HLS Stock  CAD 4.58  0.12  2.55%   
HLS Therapeutics Operating Income yearly trend continues to be very stable with very little volatility. Operating Income is likely to grow to about -6.6 M this year. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit HLS Therapeutics generates from its operations. View All Fundamentals
 
Operating Income  
First Reported
1997-03-31
Previous Quarter
-778 K
Current Value
-1.4 M
Quarterly Volatility
3.7 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check HLS Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among HLS Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 13.2 M, Interest Expense of 12.2 M or Total Revenue of 55.7 M, as well as many indicators such as Price To Sales Ratio of 1.19, Dividend Yield of 0.0102 or PTB Ratio of 0.73. HLS financial statements analysis is a perfect complement when working with HLS Therapeutics Valuation or Volatility modules.
  
This module can also supplement various HLS Therapeutics Technical models . Check out the analysis of HLS Therapeutics Correlation against competitors.

Latest HLS Therapeutics' Operating Income Growth Pattern

Below is the plot of the Operating Income of HLS Therapeutics over the last few years. Operating Income is the amount of profit realized from HLS Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of HLS Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. HLS Therapeutics' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in HLS Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Operating Income10 Years Trend
Slightly volatile
   Operating Income   
       Timeline  

HLS Operating Income Regression Statistics

Arithmetic Mean1,695,435
Geometric Mean7,383,639
Coefficient Of Variation715.03
Mean Deviation10,333,625
Median(2,465,969)
Standard Deviation12,122,822
Sample Variance147T
Range36.7M
R-Value(0.71)
Mean Square Error78.1T
R-Squared0.50
Significance0
Slope(1,700,322)
Total Sum of Squares2351.4T

HLS Operating Income History

2026-6.6 M
2025-6.9 M
2024-7.7 M
2023-10.3 M
2022-13.4 M
2021-6.2 M
2020-11.3 M

About HLS Therapeutics Financial Statements

HLS Therapeutics investors utilize fundamental indicators, such as Operating Income, to predict how HLS Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Operating Income-6.9 M-6.6 M

Other Information on Investing in HLS Stock

HLS Therapeutics financial ratios help investors to determine whether HLS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLS with respect to the benefits of owning HLS Therapeutics security.